EKSO Bionics Holdings, Inc. (EKSO) presents a deeply negative liquidation posture as of March 31, 2026. Applying standard haircuts to reported book values: cash at 100% recovers approximately $4.0M (including $0.3M restricted); accounts receivable at 90-95% yields roughly $4.1-4.3M on a gross $4.6M balance (allowance of $50K already embedded, but incremental bad-debt provisions of $298K during the quarter signal deteriorating quality); inventory at 60% yields approximately $2.8M on $4.6M book; PP&E at 50-70% yields approximately $0.6-0.8M on $1.1M net; intangibles ($1.7M finite-lived, $0.4M goodwill) and ROU assets are zeroed. Total stressed asset recovery is approximately $11.5-12.1M. Against total liabilities of $13.9M at face value—including $2.1M accounts payable, $1.7M accrued liabilities, $1.6M current deferred revenue, $2.1M current convertible debt (B. Riley note), $1.25M current Parker Hannifin installment, $1.2M total lease obligations (ASC 842, undiscounted $503K), $2.9M non-current warrant derivative liability, and $1.3M non-current deferred revenue—equity recovery is negative before addressing the $3.65M Series B Preferred Stock (carried as temporary equity at redemption-accretion value, full redemption $5.85M). The MFFAIS-computed cash liquidation value of -$5.2M and liquid liquidation value of -$0.7M are consistent with this framework. The operating liquidation value of +$4.0M reflects only the going-concern scenario and is not recoverable in a stop-operations scenario. Key deterioration since the prior 10-K (December 31, 2025): cash fell from $1.2M to $4.0M only due to the January 2026 Series B private placement ($5.3M net proceeds), masking $2.1M operating cash burn in Q1 2026. Revenue declined 37% YoY to $2.1M, operating loss widened to $5.6M, and total net loss of $6.9M includes $0.7M non-cash warrant revaluation loss and $0.1M warrant issuance finance cost, both new items in Q1 2026. A Contribution and Exchange Agreement with Applied Digital Cloud Corporation (signed February 15, 2026) is the primary strategic development; closing requires $15M minimum cash, which management acknowledges is not achievable from current operations. Management explicitly discloses going-concern substantial doubt, estimating current cash funds operations only into early Q3 2026. The B. Riley Promissory Note ($2.4M, fully current) and Series B redemption obligation ($5.85M) create compounding near-term liability pressure. Purchase obligations increased QoQ from $874K to $1.4M, adding further current claims. Filing discusses the warrant derivative liability revaluation in MD&A but the non-cash gain/loss line is separately tagged as DerivativeGainLossOnDerivativeNet. Intangible asset impairment of $750K (finite-lived) is disclosed in XBRL tags but the filing does not separately break out the timing or asset class in MD&A for Q1 2026—this appears to be a carry-forward from prior period tagging context.
▼ Community Notes